Solstice Advanced Materials (SOLS) Investor Day 2025 summary

Strategic vision and market positioning

• Positioned as a leading specialty materials company post-spin-off, leveraging a 130-year legacy, innovation, agility, and customer-centricity.

• Operates in two main segments: Refrigerants & Applied Solutions and Electronics & Specialty Materials, serving over 3,000 customers in 120+ countries.

• Targets secular growth markets including advanced computing, AI, energy evolution (nuclear), healthcare, and personal safety/defense, benefiting from regulatory and technological tailwinds.

• Maintains a diverse manufacturing footprint with 24 sites globally, ensuring supply chain resilience and customer proximity.

• Emphasizes strong customer relationships, with the largest customer accounting for less than 3% of sales.

Innovation and growth strategy

• 45% of sales come from new products, supported by over 5,700 patents and more than 300 R&D scientists across four global R&D centers.

• Increased R&D investment to drive next-generation solutions in electronics, refrigerants, healthcare, and energy.

• Focuses on application replication, customer-partnered innovation, and adjacent market expansion such as battery chemicals, advanced packaging, and thermal management for data centers.

• Established a thermal management design center to address data center and chip cooling needs, integrating solutions from chip to building level.

• Pursues both organic growth and selective bolt-on M&A aligned with strategic pillars.

Financial performance and guidance

• Achieved $3.8 billion in net sales for 2024, with a 4.4% organic sales CAGR since 2016/2017, outperforming peer median growth.

• Adjusted Standalone EBITDA estimated at $995 million for 2024, with a margin of 26.4%, and return on invested capital at 21.5%.

• Maintains a strong balance sheet with 1.5x net leverage, BB+ credit ratings, and robust cash conversion above 70%.

• 2025 guidance: $3.75–$3.85 billion in sales, 25% adjusted EBITDA margin, and $365–$415 million in CapEx, with medium-term sales growth expected in the low to mid-single digits.

• Ongoing debottlenecking and capacity expansions, including $200 million in semiconductor capacity and $33 million in medical propellant manufacturing, to support future volume growth.